Celgene (NASDAQ:CELG) has been assigned a $123.00 price target by equities researchers at Credit Suisse Group in a research note issued to investors on Thursday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s target price suggests a potential upside of 17.10% from the company’s current price.
CELG has been the topic of a number of other research reports. Royal Bank of Canada reissued a “buy” rating and issued a $173.00 target price on shares of Celgene in a research note on Thursday, October 5th. Morgan Stanley cut shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a research note on Thursday, October 5th. Robert W. Baird reissued a “buy” rating and issued a $162.00 target price on shares of Celgene in a research note on Thursday, September 21st. Cantor Fitzgerald reaffirmed a “buy” rating and set a $162.00 price objective on shares of Celgene in a research note on Tuesday, September 26th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $160.00 price objective on shares of Celgene in a research note on Friday, September 15th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $132.63.
Celgene (CELG) traded up $0.29 during trading on Thursday, reaching $105.04. 2,699,449 shares of the company’s stock were exchanged, compared to its average volume of 4,826,241. The firm has a market cap of $82,243.13, a price-to-earnings ratio of 24.95, a price-to-earnings-growth ratio of 0.81 and a beta of 1.78. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene has a 52-week low of $94.55 and a 52-week high of $147.17.
A number of hedge funds and other institutional investors have recently made changes to their positions in CELG. Thompson Davis & CO. Inc. raised its holdings in Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the period. Arcadia Investment Management Corp MI raised its holdings in Celgene by 118.7% in the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares during the period. Robecosam AG acquired a new stake in Celgene in the third quarter worth $114,000. Guidant Wealth Advisors acquired a new stake in Celgene in the third quarter worth $119,000. Finally, Capital Bank & Trust Co raised its holdings in Celgene by 166.8% in the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 517 shares during the period. Institutional investors and hedge funds own 79.74% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Celgene (CELG) Given a $123.00 Price Target by Credit Suisse Group Analysts” was posted by American Market News and is the sole property of of American Market News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/29/celgene-celg-given-a-123-00-price-target-by-credit-suisse-group-analysts.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
